RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Krabbe Disease: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Glia-enriched human brain organoids for studying developmental alterations in leukodystrophies
Elisabeth Mangiameli et al., bioRxiv (Cold Spring Harbor Laboratory) (8 October 2026)
https://doi.org/10.64898/2026.10.01.755898
- 2.
A case of Krabbe disease presenting with hydrocephalus
Harun Yıldız et al., Ege Tıp Dergisi (3 September 2026)
https://doi.org/10.19161/etd.1816288
- 3.
Correction: Caregiver-reported disease burden in Krabbe disease: evaluating outcomes of hematopoietic stem cell transplantation.
Bascou Nicholas Alexander et al., Orphanet journal of rare diseases (24 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42638118/
- 4.
Metabolomic, lipidomic, and N-glycomic analyses of a human cell model of Krabbe disease reveal treatable deficits in glycosylation and serine-ceramide metabolism.
Starosta Rodrigo et al., bioRxiv : the preprint server for biology (13 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42845430/
- 5.
Homozygosity for a Clinically Significant
Schecter Daniel R et al., International journal of neonatal screening (29 July 2026)
https://pubmed.ncbi.nlm.nih.gov/42647246/
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Krabbe Disease
Krabbe disease is a rare lysosomal storage disorder caused by galactocerebrosidase (GALC) enzyme deficiency, causing rapid and fatal demyelination of the nervous system in infants. Hematopoietic stem cell transplantation can slow progression when performed before symptom onset, making newborn screening critical.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Leukodystrophies (LKD) comprise mostly inherited white matter disorders whose developmental origins and underlying pathomechanisms remain poorly understood. Progress has been limited by restricted access to human primary tissue and by the inability of animal models to fully recapitulate human neurodevelopment. Human induced pluripotent stem cell-derived neural organoids provide an alternative approach, but most culture systems do not capture later, glia-rich developmental stages relevant to these diseases. Recent studies have shown that appropriate patterning cues and long in vitro differentiation can generate neuroglial spheroids comprising multiple neuronal and macroglial populations, including mature oligodendrocytes. Here, we adapt the human oligodendrocyte (hOLS) spheroid platform to establish 3D models of globoid cell leukodystrophy (GLD), 4H leukodystrophy (4H), and Canavan disease (CD). Here we adapt this organoid platform to establish 3D models of globoid cell leukodystrophy (GLD), 4H leukodystrophy (4H), and Canavan disease (CD). Across 150 days of differentiation, hOLS from different genetic backgrounds displayed largely comparable growth kinetics and developmental trajectories, comprising multiple neuroglial cell types with predominantly ventral forebrain and midbrain identities. Comparison of LKD and control hOLS revealed both shared and disease-specific alterations, with prominent transcriptional changes in lysosomal, metabolic, and stress-response pathways. Lineage-resolved pathway analysis further identified signatures across individual LKDs, including mitochondrial and translational stress in GLD glial lineages, disruption of RNA metabolic and cell-cycle pathways in 4H, and prominent astrocyte-centered metabolic dysregulation in CD. Our results establish hOLS as a human 3D in vitro platform for studying the impact of LKD-associated genetic variants on early neural development and for dissecting lineage-specific disease vulnerability.
Common Questions
What is Krabbe Disease?
Krabbe disease is a rare lysosomal storage disorder caused by galactocerebrosidase (GALC) enzyme deficiency, causing rapid and fatal demyelination of the nervous system in infants. Hematopoietic stem cell transplantation can slow progression when performed before symptom onset, making newborn screening critical.
How many clinical trials are available for Krabbe Disease?
RareWays currently indexes 10 clinical trials for Krabbe Disease, of which 1 is actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Krabbe Disease come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Krabbe Disease.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.